Zimmer Biomet Holdings (ZBH) Stock Forecast & Price Target

Compare

1,082 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZBH Analyst Ratings

Hold

4 Buy

11 Hold

3 Sell

Based on 18 analysts giving stock ratings to

Zimmer

Biomet Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZBH Stock 12 Month Forecast

Average Price Target

$101.15

▲(9.15% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Zimmer Biomet Holdings in the last 3 months. The average price target is $101.15 with a high forecast of $120.00 and a low forecast of $88.00. The average price target represents a 9.15% change from the last price of $92.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"87":"$87","104":"$104","121":"$121","95.5":"$95.5","112.5":"$112.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.15384615384616,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$101.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$88.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[87,95.5,104,112.5,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.92,92.23384615384616,94.54769230769232,96.86153846153846,99.17538461538462,101.48923076923077,103.80307692307693,106.11692307692309,108.43076923076923,110.74461538461539,113.05846153846154,115.37230769230769,117.68615384615384,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.92,90.78414201183432,91.64828402366864,92.51242603550295,93.37656804733729,94.2407100591716,95.10485207100592,95.96899408284024,96.83313609467456,97.69727810650888,98.5614201183432,99.42556213017752,100.28970414201184,{"y":101.15384615384616,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.92,89.77230769230769,89.62461538461538,89.47692307692307,89.32923076923078,89.18153846153847,89.03384615384616,88.88615384615385,88.73846153846154,88.59076923076923,88.44307692307693,88.29538461538462,88.14769230769231,{"y":88,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":104.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.41,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.63,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.29,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.92,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$101.15

Lowest Price Target$88.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Roman

Goldman Sachs

Sell

―

Downgraded

01/09/26

Goldman Sachs downgrades Zimmer Biomet Holdings (ZBH) to a Sell

Ryan Zimmerman

BTIG

$112

Buy

20.86%

Upside

Reiterated

01/08/26

Zimmer Biomet: Buy Rating Driven by Discounted Valuation, Lowered Expectations, and Execution Upside

Shagun Singh Chadha

RBC Capital

$101

Buy

8.99%

Upside

Reiterated

01/07/26

RBC Capital Keeps Their Buy Rating on Zimmer Biomet Holdings (ZBH)

Jayson Bedford

Raymond James

$103→

Hold

―

Downgraded

01/06/26

Zimmer Biomet Holdings (ZBH) was downgraded to a Hold Rating at Raymond James

Travis Steed

Bank of America Securities

$100

Hold

7.91%

Upside

Reiterated

01/05/26

Bank of America Securities Remains a Hold on Zimmer Biomet Holdings (ZBH)

Vijay Kumar

Evercore ISI

$94→$120

Buy

29.49%

Upside

Upgraded

01/05/26

Zimmer Biomet upgraded to Outperform from In Line at Evercore ISIZimmer Biomet upgraded to Outperform from In Line at Evercore ISI

Robbie Marcus

J.P. Morgan

$100

Hold

7.91%

Upside

Reiterated

12/23/25

Zimmer Biomet: Solid Long-Term Setup but Execution Risks and Conservative Guidance Justify Hold Rating

Caitlin Cronin

Canaccord Genuity

$90.91→$93

Hold

0.36%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Zimmer Biomet Holdings (NYSE: ZBH)

Jeff Johnson

Robert W. Baird

$117→$100

Hold

7.91%

Upside

Downgraded

12/16/25

Zimmer Biomet downgraded to Neutral from Outperform at BairdZimmer Biomet downgraded to Neutral from Outperform at Baird

Joanne Wuensch

Citi

$98→$94

Hold

1.44%

Upside

Reiterated

12/12/25

Zimmer Biomet price target lowered to $94 from $98 at CitiZimmer Biomet price target lowered to $94 from $98 at Citi

Rick Wise

Stifel Nicolaus

$110

Buy

18.70%

Upside

Reiterated

11/24/25

Stifel Nicolaus Keeps Their Buy Rating on Zimmer Biomet Holdings (ZBH)

Richard Newitter

Truist Financial

Hold

―

Reiterated

11/17/25

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK), Zimmer Biomet Holdings (NYSE: ZBH) and Hinge Health, Inc. Class A (NYSE: HNGE)

Danielle Antalffy

UBS

$96→$88

Sell

-5.04%

Downside

Reiterated

11/06/25

UBS Remains a Sell on Zimmer Biomet Holdings (ZBH)

Matt Miksic

Barclays

$105

Sell

13.31%

Upside

Reiterated

11/05/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), Kymera Therapeutics (NASDAQ: KYMR) and Zimmer Biomet Holdings (NYSE: ZBH)

Josh Jennings

TD Cowen

$104→$99

Hold

6.83%

Upside

Reiterated

11/05/25

Zimmer Biomet Holdings: Mixed Q3 Performance and Narrowed Guidance Justify Hold Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Roman

Goldman Sachs

Sell

―

Downgraded

01/09/26

Goldman Sachs downgrades Zimmer Biomet Holdings (ZBH) to a Sell

Ryan Zimmerman

BTIG

$112

Buy

20.86%

Upside

Reiterated

01/08/26

Zimmer Biomet: Buy Rating Driven by Discounted Valuation, Lowered Expectations, and Execution Upside

Shagun Singh Chadha

RBC Capital

$101

Buy

8.99%

Upside

Reiterated

01/07/26

RBC Capital Keeps Their Buy Rating on Zimmer Biomet Holdings (ZBH)

Jayson Bedford

Raymond James

$103→

Hold

―

Downgraded

01/06/26

Zimmer Biomet Holdings (ZBH) was downgraded to a Hold Rating at Raymond James

Travis Steed

Bank of America Securities

$100

Hold

7.91%

Upside

Reiterated

01/05/26

Bank of America Securities Remains a Hold on Zimmer Biomet Holdings (ZBH)

Vijay Kumar

Evercore ISI

$94→$120

Buy

29.49%

Upside

Upgraded

01/05/26

Zimmer Biomet upgraded to Outperform from In Line at Evercore ISIZimmer Biomet upgraded to Outperform from In Line at Evercore ISI

Robbie Marcus

J.P. Morgan

$100

Hold

7.91%

Upside

Reiterated

12/23/25

Zimmer Biomet: Solid Long-Term Setup but Execution Risks and Conservative Guidance Justify Hold Rating

Caitlin Cronin

Canaccord Genuity

$90.91→$93

Hold

0.36%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Zimmer Biomet Holdings (NYSE: ZBH)

Jeff Johnson

Robert W. Baird

$117→$100

Hold

7.91%

Upside

Downgraded

12/16/25

Zimmer Biomet downgraded to Neutral from Outperform at BairdZimmer Biomet downgraded to Neutral from Outperform at Baird

Joanne Wuensch

Citi

$98→$94

Hold

1.44%

Upside

Reiterated

12/12/25

Zimmer Biomet price target lowered to $94 from $98 at CitiZimmer Biomet price target lowered to $94 from $98 at Citi

Rick Wise

Stifel Nicolaus

$110

Buy

18.70%

Upside

Reiterated

11/24/25

Stifel Nicolaus Keeps Their Buy Rating on Zimmer Biomet Holdings (ZBH)

Richard Newitter

Truist Financial

Hold

―

Reiterated

11/17/25

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK), Zimmer Biomet Holdings (NYSE: ZBH) and Hinge Health, Inc. Class A (NYSE: HNGE)

Danielle Antalffy

UBS

$96→$88

Sell

-5.04%

Downside

Reiterated

11/06/25

UBS Remains a Sell on Zimmer Biomet Holdings (ZBH)

Matt Miksic

Barclays

$105

Sell

13.31%

Upside

Reiterated

11/05/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), Kymera Therapeutics (NASDAQ: KYMR) and Zimmer Biomet Holdings (NYSE: ZBH)

Josh Jennings

TD Cowen

$104→$99

Hold

6.83%

Upside

Reiterated

11/05/25

Zimmer Biomet Holdings: Mixed Q3 Performance and Narrowed Guidance Justify Hold Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zimmer Biomet Holdings

1 Month

xxx

Success Rate

15/25 ratings generated profit

Average Return

+0.82%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +0.82% per trade.

3 Months

xxx

Success Rate

10/15 ratings generated profit

Average Return

-0.48%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of -0.48% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

15/28 ratings generated profit

Average Return

+4.15%

reiterated a buy rating 2 months ago

Copying Rick Wise's trades and holding each position for 1 Year would result in 53.57% of your transactions generating a profit, with an average return of +4.15% per trade.

2 Years

xxx

Success Rate

12/15 ratings generated profit

Average Return

+9.99%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +9.99% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZBH Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZBH has received 12 Buy Ratings, 16 Hold Ratings, and 2 Sell Ratings. ZBH average Analyst price target in the past 3 months is 101.15.

Each month's total comprises the sum of three months' worth of ratings.

ZBH Financial Forecast

ZBH Earnings Forecast

Next quarter’s earnings estimate for ZBH is $2.40 with a range of $2.35 to $2.45. The previous quarter’s EPS was $1.90. ZBH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ZBH has Performed in-line its overall industry.

ZBH Sales Forecast

Next quarter’s sales forecast for ZBH is $2.22B with a range of $2.20B to $2.24B. The previous quarter’s sales results were $2.00B. ZBH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ZBH has Performed in-line its overall industry.

ZBH Stock Forecast FAQ

What is ZBH’s average 12-month price target, according to analysts?

Based on analyst ratings, Zimmer Biomet Holdings’s 12-month average price target is 101.15.

What is ZBH’s upside potential, based on the analysts’ average price target?

Zimmer Biomet Holdings has 9.15% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZBH a Buy, Sell or Hold?

Zimmer Biomet Holdings has a consensus rating of Hold which is based on 4 buy ratings, 11 hold ratings and 3 sell ratings.

What is Zimmer Biomet Holdings’s price target?

The average price target for Zimmer Biomet Holdings is 101.15. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $88.00. The average price target represents 9.15% Increase from the current price of $92.67.

What do analysts say about Zimmer Biomet Holdings?

Zimmer Biomet Holdings’s analyst rating consensus is a Hold. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of ZBH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Zimmer Biomet Holdings (ZBH) Stock Forecast & Price Target

ZBH Analyst Ratings

ZBH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zimmer Biomet Holdings

ZBH Analyst Recommendation Trends

ZBH Financial Forecast

ZBH Earnings Forecast

ZBH Sales Forecast

ZBH Stock Forecast FAQ

Detailed List of Analyst Forecasts